Xeris Pharmaceuticals presents new data on developmental RTU glucagon
Xeris Pharmaceuticals announced it is presenting data on its developmental ready-to-use room-temperature stable liquid glucagon at two medical conferences. Xeris will present the first data from its Phase 2 study of RTU, room-temperature stable liquid glucagon for congenital hyperinsulinemia during ENDO 2019. As part of this randomized, placebo-controlled study, five patients with CHI under 1 year of age were enrolled to receive Xeris' RTU glucagon delivered continuously through an Omnipod infusion pump to prevent hypoglycemia and to lower supplemental glucose requirements, via reductions in intravenous glucose infusion rates. The company said, "Treated patients had a positive clinical response compared to those receiving placebo, and follow-up open-label treatment resulted in a clinically meaningful response in all evaluable patients." Results of a Xeris budget impact model on the estimated potential reduction in costs associated with use of its RTU room-temperature stable liquid glucagon will be presented in a poster during the Academy of Managed Care Pharmacy's AMCP Managed Care & Specialty Pharmacy Annual Meeting. The model was developed to estimate the economic impact of open coverage of Gvoke HypoPen for the treatment of severe hypoglycemia events as an alternative to currently marketed glucagon emergency kits . The company said, "With its positive functional efficacy profile, the results of the model illustrate the potential financial benefits for open coverage of glucagon rescue pen. The health utilization data also supports physicians to increase patient access to completed and filled glucagon prescriptions, in order to optimize patient outcomes. Results of the analysis indicate that significant overall cost savings may be achieved with use of the Xeris GRP." A New Drug Application for Xeris' lead product candidate, Gvoke HypoPen for the treatment of severe hypoglycemia, is currently under review with the U.S. Food and Drug Administration, with a decision expected during Q2.